What is it about?
Diffuse intrinsic pontine glioma (DIPG) is a type of childhood brain cancer that is extremely difficult to treat. This paper investigates the use of the drug palbociclib, in combination with the rapamycin analogue temsirolimus, and demonstrates the synergistic antiproliferative effects of CDK4/6 and mTOR inhibitors in DIPG cancer cells. Direct infusion of palbociclib into the brain, in combination with systemic delivery of temsirolimus, could potentially be utilised in future as a new treatment for DIPG.
Featured Image
Why is it important?
Nine out of ten children diagnosed with DIPG do not survive beyond two years. The use of surgical interventions to treat DIPG is typically not not a viable option, due to the location of the tumours and dangers associated with operating on critically important areas of the brain. Likewise, standard radiotherapy and chemotherapy drugs used to treat adult high grade gliomas are not effective against DIPG. Hence, new drug treatments are urgently required. Here we demonstrate a promising new targeted combination chemotherapy, aimed specifically at treating DIPG.
Read the Original
This page is a summary of: Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity, Cancer Management and Research, September 2018, Dove Medical Press,
DOI: 10.2147/cmar.s167095.
You can read the full text:
Contributors
The following have contributed to this page
